Britain’s healthcare cost watchdog NICE said on Friday it had changed its mind and decided to recommend Sanofi’s prostate cancer drug Jevtana after the French company agreed to a further discount.   The National Institute for Health and Care Excellence (NICE) said the improved discount was “an excellent example of how pharma companies can work […]

New heart drugs hailed as breakthrough treatments by researchers are struggling to gain traction among prescribing doctors, posing a headache for makers such as Novartis, which reported more weak sales for its Entresto medicine.

Hyderabad, India and Princeton, NJ, USA. April 19, 2016 — Promius Pharma LLC, a subsidiary of Dr. Reddy’s Laboratories, announced today that ZEMBRACE SymTouch is now commercially available in the U.S. ZEMBRACE SymTouch is a prefilled, low-dose, ready-to-use, 2-step autoinjector containing 3 mg of sumatriptan, a selective 5-HT1B/ID receptor agonist. Because ZEMBRACE SymTouch is a […]

U.S. annual spending on prescription medicines will increase 22 percent over the next five years, climbing as high as $400 billion in 2020, according to a report released by IMS Health.

U.S. doctors and hospitals throw out almost $3 billion (roughly 2.7 billion euros) in unused cancer drugs each year because the medicines come in supersized single-use packages and excess medicine must be discarded for safety reasons, a recent paper suggests. Researchers focused on 20 expensive medicines that are given by injection or intravenous drip and […]

A cancer drug originally discovered in Britain has finally been endorsed for treating advanced prostate cancer before chemotherapy on the country’s state health service in a change of heart by the cost agency NICE.

U.S. spending on prescription drugs rose 5.2 percent in 2015 – including the impact of rebates – driven by an 18 percent increase in specialty drugs, Express Scripts Holding Co. said.

New York state Attorney General Eric Schneiderman’s office has asked 16 health insurers for documentation on patients who have been denied coverage of drugs used to cure hepatitis C, a person familiar with the matter told Reuters on Wednesday. Schneiderman’s office also requested details on procedures followed by the companies to authorize the drugs used […]

A new leukemia drug viewed by industry experts as a future blockbuster has been rejected by Britain’s healthcare cost-effectiveness agency NICE, which said it could not be confident the medicine represented an effective use of resources. Imbruvica has a list price of 55,954.50 pounds ($78,000) a year, although it is being offered at an undisclosed […]

AstraZeneca has sold rights to a non-core drug to a unit of Kyowa Hakko Kirin for an upfront payment of $70 million, a day after getting $500 million for two ageing heart medicines.   The British-based drugmaker has been divesting peripheral products to help pay the bills as it invests in new medicines, while taking […]